SV2A and psychiatric disorder: To date, longitudinal studies have shown decreases in SV2A PET measures and worsening of symptoms in neurodegenerative illnesses, supporting a causal role for synaptic changes in these disorders, but there have not been longitudinal studies in psychiatric disorders.